Just finished the article; couldn't agree more. I think in 3-4 years this could easily be a $25 stock unless some M&A activity happens before then. The CCO position adds further validation that XOMA's first commercial target is likely to be approved and get traction. This isn't a quick pop scenario as important clinical data won't be available until late 2013. No point in getting too excited about normal ups/downs in the interim. I will continue to accumulate when it pulls down to the $2.50 area, as it seems to do when the risk-off trade "algo" programs kick in. And, they will kick in between now and early 2014.